Pics 4: WBC/BMF/MPN/CML Flashcards by Victoria DeVito

Q

Neutrophil life cycle and inherited neutrophil disorders

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Neutrophilia causes: acute and chronic

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

hereditary and acquired causes of HLH

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Diagnostic criteria HLH

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Neutropenia inherited and acquired

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

GATA2 vs SAMD9 associated findings

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Inherited BMF chapter table 1

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Inherited BMF chapter table 2

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HES and CEL treatment

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

ICC hypereosinophilia classification

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Fusion driven eosinophilic neoplasms

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Approach to eosinophilia pt

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Eosinophilia definitions
Hypreosinophilia, primary, secondary, HES

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Secondary causes eosinophilia

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Eosinophilia summary

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Drugs causing agranulocytosis

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Leukocytosis differential

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Mgmt neutropenia

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Congenital neutropenia and genes

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Neutropenia diagnostic algorithm

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Mechanisms of neutrophil function/dysfunction

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Leukocytosis summary slide

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HLH diagnostic criteria

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HLH pathophys, multifactorial

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Optimized HLH inflammatory index [OHI]

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

H score for HLH
components

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Jak inhibitors in HLH

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Therapy for HLH principles and based on etiology

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HLH therapy

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Treatment of hyper inflammatory syndrome after IEC

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Post IEC hyperinflammatory syndrome, pathophys

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

HLH take home points

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Ddx pancytopenia

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Inherited vs Acquired bone marrow failures

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

History clues to acquired vs inherited BMF

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Initial eval of BMF patient

A

How well did you know this?

1

Not at all

2

3

4

5

Perfectly

Q

Acquired AA criteria
nonsecure
severe
very severe

A

Q

Treatment severe AA <40yo

A

Q

AA vs hypocellular MDS clues

A

Q

iBMF disorders quick testing guide

A

Q

iBMF table, inheritance extrahematopoietic manifestations [EHM] and malignancy risk

A

Q

Complement inhibitors chart
5 types

A

Q

Causes secondary erythrocytosis

A

Q

WHO criteria for PV

A

Q

Mgmt ET

A

Q

Management PV

A

Q

Diagnostic workup of erythrocytosis

A

Q

WHO dx ET

A

Q

Approach to thrombocytosis

A

Q

Mgmt MF

A

Q

WHO dx CNL

A

Q

WHO dx PMF

A

Q

Mutations in MPNs
which disorders
other common mutations?

A

Q

Distinguishing features of classical MPNs

A

Q

PV survival by risk factors

A

Q

IPSET for ET

A

Q

Mgmt PV

A

Q

Secondary causes of erythrocytosis

A

Q

Mgmt ET

A

Q

Ddx MF

A

Q

Mgmt MF

A

Q

Myeloid/lymphoid neoplasms associated with eosinophilia by TKGF
Which respond to TKI

A

Q

Systemic mastocytosis diagnosis and classification table

A

Q

ICC ET and post ET MF

A

Q

Hypereosinophilias table, classification and mgmt

A

Q

ICC PV and post-PV MF

A

Q

ICC MPNs categories, My/ly-N-E-TKGF, Mastocytosis

A

Q

ICC PMF diagnosis
prefibrotic and overt

A

Q

ICC CNL

A

Q

ICC MPN-U

A

Q

ICC CEL-NOS

A

Q

ICC iHES

A

Q

ICC my/ly neoplasms with eos and TKGFs

A

Q

WHO5 hypereosinophilia algorithm

A

Q

ICC SM diagnosis

A

Q

ICC SM-AMN

A

Q

WHO5 features of ET vs prefibrotic MF on BMBx

A

Q

Types of testing in CML [3]
Advantages of each, when to use, what sample?

A

Q

Frontline trials for CML-CP
Drug name, dose, trial name and comparator arm

A

Q

Criteria for AP CML

A

NOTE
WHO5 has removed CML-AP
focuses more on the higher risk features of CML, including ACAs
CML-BP is >20% myeloblasts, extramedullary disease or increased lymphoblasts in blood or BM

Q

CML-CP 2nd+ lines of therapy, options

A

Q

Cutoff for MMR, MR4, MR4.5 and MR5

Optimal response at 3,6,12 months

A

Q

TKI side effects

A

Q

Discontinuation of TKI, trials

A

General guidelines:
- Rx>3y
- >2y in MR4+
- adult
- able to monitor transcript #closely

Q

Resistance to TKIs, which one to choose next?

A

Q

Accelerated and blast phase features
- per ICC
- other features of AP

A

Other AP features:
- baso>19%
- plt<100
- WBC or spleen not responding to TKI
- clonal evolution

Q

Response definitions in CML

A

Q

Targets by colour in CML
3 months, 6 months, 12 months

A

Q

Targets table in front line CML
3,6,12 months

A

Q

Trials for frontline 2nd gen TKIs
Dasatinib
Nilotinib
Bosutinib

A

Q

Accelerated phase treatment: which TKIs
Special dosing?

A

Q

Criteria for TKI discontinuation
ELN 2020
NCCN 2022

A